Precision Medicine

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

HistoSonics begins a landmark trial for a non-invasive BPH therapy that uses focused ultrasound to mechanically destroy tissue without incisions or heat.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

NUCOT celebrates patients thriving 25+ years post-transplant, setting new global benchmarks in survival rates through advanced care and resilience.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

As Mochi Health takes the stage at a top women's health summit, a look behind the PR reveals a company battling rapid growth and customer complaints.

After its pivotal trial for ersodetug missed its primary endpoint, Rezolute gets a rare nod from the FDA to submit full data, igniting new hope.

A Denver clinic now offers Therapeutic Plasma Exchange for anti-aging. But does the science back up the high-cost promise of turning back the clock?

New research on ILUMYA, LEQSELVI, and WINLEVI shows sustained efficacy and faster results, aiming to transform treatment for millions of patients.

A landmark partnership is scaling a 'one-drug, many-diseases' therapy, revealing how logistics, not just labs, are key to the future of medicine.

A $520K state grant will provide firefighters with a new AI-powered blood test, highlighting a major push to protect high-risk first responders.

New 3-year trial data shows UCB's BIMZELX prevents painful flares in most HS patients, highlighting a critical window for early intervention.

The pharma giant's acquisition of Excellergy and its first-in-class Exl-111 could revolutionize treatment for millions with severe, debilitating allergies.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

A groundbreaking study of 78,000 people shows most with acne and psoriasis manage their conditions alone, outside the clinic. Here's what it means.

A US firm is bringing embryo screening for chronic diseases to major IVF networks, sparking debate on the future of family planning and genetic health.

Healthcare powerhouse Terri Cooper joins Morphic Medical's board, a strategic move to navigate clinical trials for its non-surgical RESET diabetes therapy.

A new lithium formula boosts brain delivery in a key trial, offering hope for safer, more effective treatments for Alzheimer's, bipolar disorder, and more.

A new RNA drug shows promise by reducing harmful belly fat while preserving muscle, but modest overall weight loss in early trials spooks investors.